Doris Cully, PhD, Joins Cardioxyl as Vice President, Preclinical Development

Former Director, Early Development and Discovery Sciences at Merck

Life Science Partner recruited, Doris Cully, PhD an innovative drug discovery research leader, to become Vice President, Preclinical Development at Cardioxyl Pharmaceuticals.

Developing congestive heart failure therapies, Cardioxyl produces the most advanced technology in the development of proprietary nitroxyl donors for the treatment of acute decompensated heart failure (ADHF).

Cully has an extensive background in biochemistry, cell and molecular biology, and translational biomarkers. Prior to accepting the position at Cardioxyl, Cully was the Director, Early Development and Discovery Sciences at Merck where she specialized in Cardiovascular Diseases such as hypertension, acute-decompensated heart failure, and hypertension-associated kidney disease.

In her new role at Cardioxyl, Cully will report to the Chief Scientific Officer and lead a team for the first oral HNO program, including indications for post-acute congestive heart failure and chronic heart failure.

“Cully is a savvy, hands-on scientist who has considerable experience in developing drugs from target to IND,” said Tom Callaway, MD, President of Life Science Partner.  “She can call the tough shots – including doing the critical experiments that results that illuminate critical decision points.”

After being awarded her Bachelor of Science Degree from The State University of New York at Stony Brook, Cully earned her PhD in Biomedical Sciences